Advertisement
Canada markets close in 4 hours 48 minutes
  • S&P/TSX

    22,160.70
    +213.29 (+0.97%)
     
  • S&P 500

    5,156.76
    +28.97 (+0.56%)
     
  • DOW

    38,743.15
    +67.47 (+0.17%)
     
  • CAD/USD

    0.7323
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    78.62
    +0.51 (+0.65%)
     
  • Bitcoin CAD

    86,124.92
    -1,361.33 (-1.56%)
     
  • CMC Crypto 200

    1,371.06
    +58.43 (+4.45%)
     
  • GOLD FUTURES

    2,329.20
    +20.60 (+0.89%)
     
  • RUSSELL 2000

    2,061.39
    +25.67 (+1.26%)
     
  • 10-Yr Bond

    4.5060
    +0.0060 (+0.13%)
     
  • NASDAQ

    16,255.23
    +98.90 (+0.61%)
     
  • VOLATILITY

    13.83
    +0.34 (+2.52%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     
  • CAD/EUR

    0.6792
    +0.0005 (+0.07%)
     

Longeveron to Present at the Planet MicroCap Showcase

Longeveron
Longeveron

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.

Details for the Company’s presentation:

 

Date:

Wednesday, May 1, 2024

 

Time:

4:30 p.m. PT

 

Webcast:

Click Here

 

 

 

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

If you would like to book 1x1 investor meetings with Longeveron Inc. and to attend the Planet MicroCap Showcase: VEGAS 2024, please register here: https://planetmicrocapshowcase.com/signup.

ADVERTISEMENT

1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:

Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com